Sun Pharma and Philogen sign global licensing agreement for Fibromun
Agreement focuses on global commercialisation of anti-cancer immunotherapy
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Philogen
Submission of Nidlegy marketing authorisation application validated by EMA
The first marketing authorisation application of Nidlegy for the treatment of locally advanced fully resectable melanoma was…
Nidlegy Phase III PIVOTAL trial shows postive results for patients with locally advanced fully…
Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone
Sun Pharma, Philogen sign pact to commercialise specialty product, NIDLEGY in Europe, Australia and…
Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for…